Prelude Therapeutics (PRLD) Net Income towards Common Stockholders (QoQ) (2019 - 2026)
Prelude Therapeutics (PRLD) Net Income towards Common Stockholders (QoQ) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Prelude Therapeutics | 322.24 Mn | 177.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.49% |
| Dec 31, 2025 | 56.97% |
| Sep 30, 2025 | 22.85% |
| Jun 30, 2025 | 5.36% |
| Mar 31, 2025 | -67.47% |
| Dec 31, 2024 | 55.07% |
| Sep 30, 2024 | 4.22% |
| Jun 30, 2024 | -2.86% |
| Mar 31, 2024 | -105.05% |
| Dec 31, 2023 | -5.21% |
| Sep 30, 2023 | 4.80% |
| Jun 30, 2023 | 1.09% |
| Mar 31, 2023 | 73.54% |
| Dec 31, 2022 | -239.81% |
| Sep 30, 2022 | -14.38% |
| Jun 30, 2022 | 10.64% |
| Mar 31, 2022 | 61.63% |
| Dec 31, 2021 | 36.30% |
| Sep 30, 2021 | -6.99% |
| Jun 30, 2021 | 37.46% |